cervicalcancer60y.o.40-70 y.o.,ASCVD ≥10%, lowbleeding riskq5y≥ 140mg/dLHIVaspirin< 60y.o.Tyrer-Cuzickmodelstatin40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsFractureRiskAssessmentTool40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factor≤q2ydementia≥5.7%40y.o.Gailmodeltobaccouse40-59 y.o.,ASCVD ≥10%, lowbleeding riskbreastcancer≥ 126mg/dLcardiovasculardiseasehormonetherapydepression1 dose; 2doses (2-6monthsapart) ifimmunocompTimedup andgo testtamoxifen≥ 100mg/dL52y.o.40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorHepatitisCinsufficientevidenceforscreeningq1yq3yHepatitisBlungcancerherpeszostercolorectalcancerdyslipidemia≥20%PREVENTequation75y.o.aromataseinhibitors50y.o.3%pneumococcalcommunity-dwelling,postmenopausalwomenovariancancerq1ymammogramanxietyq15yq2ydiabetesoverweight/ obesity≥6.5%≥ 200mg/dLhypertension2 doses,2-6monthsapart65y.o.q1-2ymammogrambased on lifeexpectancy /health statusmultidoseinitial series,then 1 doseat 2-6monthswomenage 55-64 y.o.raloxifene≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorscervicalcancer60y.o.40-70 y.o.,ASCVD ≥10%, lowbleeding riskq5y≥ 140mg/dLHIVaspirin< 60y.o.Tyrer-Cuzickmodelstatin40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsFractureRiskAssessmentTool40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factor≤q2ydementia≥5.7%40y.o.Gailmodeltobaccouse40-59 y.o.,ASCVD ≥10%, lowbleeding riskbreastcancer≥ 126mg/dLcardiovasculardiseasehormonetherapydepression1 dose; 2doses (2-6monthsapart) ifimmunocompTimedup andgo testtamoxifen≥ 100mg/dL52y.o.40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorHepatitisCinsufficientevidenceforscreeningq1yq3yHepatitisBlungcancerherpeszostercolorectalcancerdyslipidemia≥20%PREVENTequation75y.o.aromataseinhibitors50y.o.3%pneumococcalcommunity-dwelling,postmenopausalwomenovariancancerq1ymammogramanxietyq15yq2ydiabetesoverweight/ obesity≥6.5%≥ 200mg/dLhypertension2 doses,2-6monthsapart65y.o.q1-2ymammogrambased on lifeexpectancy /health statusmultidoseinitial series,then 1 doseat 2-6monthswomenage 55-64 y.o.raloxifene≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. cervical cancer
  2. 60 y.o.
  3. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  4. q5y
  5. ≥ 140 mg/dL
  6. HIV
  7. aspirin
  8. < 60 y.o.
  9. Tyrer-Cuzick model
  10. statin
  11. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  12. Fracture Risk Assessment Tool
  13. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  14. ≤ q2y
  15. dementia
  16. ≥ 5.7%
  17. 40 y.o.
  18. Gail model
  19. tobacco use
  20. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  21. breast cancer
  22. ≥ 126 mg/dL
  23. cardiovascular disease
  24. hormone therapy
  25. depression
  26. 1 dose; 2 doses (2-6 months apart) if immunocomp
  27. Timed up and go test
  28. tamoxifen
  29. ≥ 100 mg/dL
  30. 52 y.o.
  31. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  32. Hepatitis C
  33. insufficient evidence for screening
  34. q1y
  35. q3y
  36. Hepatitis B
  37. lung cancer
  38. herpes zoster
  39. colorectal cancer
  40. dyslipidemia
  41. ≥ 20%
  42. PREVENT equation
  43. 75 y.o.
  44. aromatase inhibitors
  45. 50 y.o.
  46. 3%
  47. pneumococcal
  48. community-dwelling, postmenopausal women
  49. ovarian cancer
  50. q1y mammogram
  51. anxiety
  52. q15y
  53. q2y
  54. diabetes
  55. overweight / obesity
  56. ≥ 6.5%
  57. ≥ 200 mg/dL
  58. hypertension
  59. 2 doses, 2-6 months apart
  60. 65 y.o.
  61. q1-2y mammogram based on life expectancy / health status
  62. multidose initial series, then 1 dose at 2-6 months
  63. women age 55-64 y.o.
  64. raloxifene
  65. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors